Top Wall Street analysts changed their outlook on these top names.

For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

HC Wainwright & Co. analyst Arthur He upgraded Prime Medicine, Inc (NASDAQ:PRME) from Neutral to Buy and announced a price target of $8.

Prime Medicine shares closed at $3.43 on Friday.

See how other analysts view this stock.